NASDAQ:APTX - Aptinyx Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.25
  • Forecasted Upside: 291.37 %
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$3.13
▼ -0.05 (-1.57%)
1 month | 3 months | 12 months
Get New Aptinyx Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for APTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for APTX

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$12.25
▲ +291.37% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aptinyx in the last 3 months. The average price target is $12.25, with a high forecast of $15.00 and a low forecast of $7.00. The average price target represents a 291.37% upside from the last price of $3.13.
Buy
The current consensus among 7 contributing investment analysts is to buy stock in Aptinyx.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/2/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/31/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/29/2019
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/27/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/23/2020

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/21/2020CowenReiterated RatingBuyMedium
i
10/20/2020SVB LeerinkBoost Price TargetOutperform$12.00 ➝ $14.00Low
i
10/14/2020JPMorgan Chase & Co.Initiated CoverageNeutralMedium
i
10/1/2020William BlairReiterated RatingBuyLow
i
Rating by M. Minter at William Blair
8/14/2020BMO Capital MarketsReiterated RatingBuy$13.00Medium
i
7/1/2020SunTrust BanksInitiated CoverageBuy$15.00High
i
6/18/2020HC WainwrightReiterated RatingBuy$7.00High
i
Rating by Ram Selvaraju at HC Wainwright
5/7/2020William BlairInitiated CoverageOutperformMedium
i
Rating by M. Minter at William Blair
4/29/2020HC WainwrightInitiated CoverageBuy$7.00High
i
Rating by R. Selvaraju at HC Wainwright
11/14/2019CowenReiterated RatingBuyHigh
i
9/12/2019WedbushInitiated CoverageOutperform$7.00High
i
Rating by L. Chico at Wedbush
8/13/2019JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightHigh
i
6/20/2019SVB LeerinkInitiated CoverageOutperform ➝ Outperform$12.00High
i
Rating by M. Goodman at SVB Leerink LLC
6/10/2019CowenReiterated RatingBuyHigh
i
4/30/2019Cantor FitzgeraldReiterated RatingBuyLow
i
Rating by Charles Duncan at Cantor Fitzgerald
3/22/2019BMO Capital MarketsReiterated RatingOutperformHigh
i
Rating by Gary Nachman at BMO Capital Markets
3/22/2019Cantor FitzgeraldLower Price TargetOverweight ➝ Overweight$18.00 ➝ $12.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
1/18/2019BMO Capital MarketsLower Price TargetOutperform$18.00Low
i
1/17/2019SVB LeerinkLower Price TargetOutperform$35.00 ➝ $22.00High
i
Rating by G. Porges at SVB Leerink LLC
1/17/2019JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$30.00 ➝ $8.00High
i
1/16/2019Cantor FitzgeraldReiterated RatingBuy$40.00High
i
Rating by C. Duncan at Cantor Fitzgerald
12/3/2018Cantor FitzgeraldReiterated RatingBuy$40.00Low
i
Rating by C. Duncan at Cantor Fitzgerald
11/14/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$40.00High
i
Rating by C. Duncan at Cantor Fitzgerald
7/16/2018SVB LeerinkInitiated CoverageOutperform$35.00Low
i
Rating by G. Porges at SVB Leerink LLC
7/16/2018CowenInitiated CoverageOutperformHigh
i
7/16/2018JPMorgan Chase & Co.Initiated CoverageOverweight$30.00Low
i
7/16/2018BMO Capital MarketsInitiated CoverageOutperform$32.00Low
i
(Data available from 10/23/2015 forward)
Aptinyx logo
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder. The company has a collaboration agreement with Allergan plc. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.
Read More

Today's Range

Now: $3.13
$3.05
$3.22

50 Day Range

MA: $3.45
$3.05
$4.30

52 Week Range

Now: $3.13
$1.60
$6.47

Volume

1,512,432 shs

Average Volume

603,621 shs

Market Capitalization

$146.99 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.21